This report contains market size and forecasts of SERD (Selective Estrogen Receptor Degrader) Drugs in Global, including the following market information:
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global SERD (Selective Estrogen Receptor Degrader) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
RAD1901 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of SERD (Selective Estrogen Receptor Degrader) Drugs include Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG and InventisBio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the SERD (Selective Estrogen Receptor Degrader) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, by Type, 2021 (%)
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, by Application, 2021 (%)
First-Line Treatment
Second-Line Treatment
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies SERD (Selective Estrogen Receptor Degrader) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies SERD (Selective Estrogen Receptor Degrader) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy's Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals